Labtec has initiated a multicentric, randomised, open label study Phase II study for its Sufentanil transdermal patch.
Sufentanil TDS is a matrix-type transdermal patch with the active ingredient sufentanil, a highly potent opioid analgesic that is used as an injection or infusion for anesthesia and analgesia.
The Phase II study is expected to evaluate efficacy and safety of Sufentanil TDS against standard treatment in patients with chronic cancer pain.
On 4 June 2010, Labtec has entered into a strategic development partnership with hameln rds, Hameln, Germany, under which hameln rds will perform all necessary development steps jointly with Labtec to bring the product through phase II.
Labtec managing director Ingo Lehrke said that they were expecting to see their Sufentanil TDS move forward.
“Sufentanil is a potent drug and offers various advantages in terms of safety and efficacy for chronic pain treatment with a transdermal system,” Lehrke said.
Labtec managing director Peter Klaffenbach said that all studies would be organised and realised at hameln rds’ research and development site in Modra, Slovakia.